文献速递主动脉疾病

B型主动脉夹层早期TEVAR全国性结局

Nationwide outcomes of early thoracic endovascular aortic repair for type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2025-10-31

这项基于新西兰全国公立医院数据的回顾性研究纳入2010至2022年420例急性B型主动脉夹层患者,评估早期胸主动脉腔内修复(TEVAR)的长期生存与再干预。结果显示早期TEVAR与复杂性TBAD调整后全因死亡率降低相关,但在高风险和非复杂性TBAD中未见生存获益,且无论初始药物或TEVAR治疗,进一步主动脉干预需求均较高。

要点

  • 复杂性TBAD早期TEVAR与更低调整后全因死亡率相关(HR 0.06)。
  • 高风险和非复杂性TBAD早期TEVAR未见显著生存获益。
  • 无论初始药物或TEVAR,TBAD进一步主动脉干预需求均较高。

核心结论

  • 早期TEVAR与复杂性TBAD调整后全因生存改善相关,但在高风险和非复杂性TBAD中未见此获益。
  • 无论初始药物或TEVAR治疗,TBAD进一步主动脉干预需求均较高。

研究设计与样本

  • 基于新西兰全国最低数据集(NMDS)的回顾性人群研究,纳入2010至2022年急性TBAD成人患者。
  • 共纳入420例患者,平均年龄64.3岁,女性占37.4%,复杂性TBAD占22.4%。
  • 早期TEVAR定义为索引夹层后90天内手术,采用Cox比例风险模型分析全因死亡和再干预。

主要发现

  • 初始治疗为药物70.5%、TEVAR 26.0%、开放主动脉修复3.6%,中位随访3.2年(IQR 1.4-6.3)。

关键数值与推荐

  • 复杂性TBAD定义为临床灌注不良或破裂征象。
  • 高风险TBAD定义为间隔影像示主动脉快速扩张、难治性高血压或疼痛、或影像学灌注不良。
  • 非复杂性TBAD为无上述特征者。
  • 早期TEVAR定义为索引夹层后90天内手术。

临床怎么用

  • 对复杂性TBAD可考虑早期TEVAR以改善调整后全因生存。
  • 对高风险和非复杂性TBAD,早期TEVAR的生存获益未得到证实,决策需个体化。
  • 无论初始治疗选择药物或TEVAR,均应持续监测再干预需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Early endovascular repair of the thoracic aorta (TEVAR) is the standard-of-care for complicated type B aortic dissection (cTBAD) but remains controversial in high-risk (hrTBAD) and uncomplicated TBAD (uTBAD). The aim of this study was to evaluate long-term survival and determine risk factors associated with survival and reintervention in cTBAD, hrTBAD, and uTBAD. METHODS: This population-based retrospective study included adults with acute TBAD from 2010 to 2022 in the National Minimum Dataset (NMDS), a database of all public hospital admissions across Aotearoa New Zealand. Chronic, traumatic, iatrogenic, or incidental TBAD and intramural hematoma without dissection were excluded. Clinical records were manually reviewed to verify diagnoses, survival, and comorbidities. Patients were classified as cTBAD if they had clinical malperfusion or signs of rupture, hrTBAD if there was rapid aortic expansion on interval imaging, refractory hypertension or pain, or radiological malperfusion, and uTBAD in the absence of these features. An early TEVAR was defined as a procedure within 90 days from the index dissection. Cox proportional hazard models were used for all-cause mortality and the need for further intervention. RESULTS: A total of 420 patients with acute TBAD were included (mean age, 64.3 years; 37.4% female; 22.4% with cTBAD). Initial management was medical in 70.5%, TEVAR in 26.0%, and open aortic repair in 3.6%. The median follow-up time was 3.2 years, accounting for mortality (interquartile range, 1.4-6.3 years). TEVAR was associated with lower adjusted all-cause mortality in cTBAD compared with best medical therapy (hazard ratio [HR], 0.06; 95% confidence interval [CI], 0.01-0.28; P < .001), but not in uTBAD (HR, 0.89; 95% CI, 0.39-2.00; P = .770) or hrTBAD (HR, 0.49; 95% CI, 0.20-1.19; P = .115). TEVAR had a similar need for further intervention compared with best medical therapy in hrTBAD (HR, 0.66; 95% CI, 0.19-2.27; P = .513) and uTBAD (HR, 2.36; 95% CI, 0.82-6.81; P = .114). CONCLUSIONS: This nationwide study found early TEVAR is associated with increased adjusted all-cause survival in cTBAD, but not in hrTBAD or uTBAD. The need for further aortic intervention in TBAD remains high regardless of initial medical or TEVAR management.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Xu W, Haran C, Lim E, et al. Nationwide outcomes of early thoracic endovascular aortic repair for type B aortic dissection. J Vasc Surg. 2025. PMID: 41177275. doi:10.1016/j.jvs.2025.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。